Results of A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of The Efficacy And Safety of Sirukumab, An Anti-IL-6 Cytokine Monoclonal Antibody, In Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment (Sirround-D)

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Disease Modifying ◽

Rheumatic Drug

SAT0145 Efficacy and Safety of Sirukumab in Patients with Active Rheumatoid Arthritis despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of A Randomized, Double-Blind, Placebo-Controlled Study: Table 1.

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2016-eular.3741 ◽

2016 ◽

Vol 75 (Suppl 2) ◽

pp. 717.1-717

Author(s):

T. Takeuchi ◽

C. Thorne ◽

G. Karpouzas ◽

S. Sheng ◽

W. Xu ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Drug Treatment ◽

Controlled Study ◽

Efficacy And Safety ◽

Treatment Results ◽

Double Blind ◽

Double Blind Placebo ◽

Disease Modifying ◽

Rheumatic Drug

Faculty Opinions recommendation of Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727328077.793564275 ◽

2019 ◽

Author(s):

Ladislav Senolt

Keyword(s):

Rheumatoid Arthritis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Parallel Group

OP0234 EFFICACY AND SAFETY OF BRODALUMAB, AN ANTI-INTERLEUKIN-17 RECEPTOR A MONOCLONAL ANTIBODY, IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: A 16 WEEK RESULTS OF A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

10.1136/annrheumdis-2019-eular.6888 ◽

2019 ◽

Cited By ~ 2

Author(s):

James Cheng-Chung Wei ◽

Tae-Hwan Kim ◽

Mitsumasa Kishimoto ◽

Takuya Morishige ◽

Naoki Ogusu ◽

...

Keyword(s):

Monoclonal Antibody ◽

Axial Spondyloarthritis ◽

Controlled Study ◽

Interleukin 17 ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

228. Secukinumab, A Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicentre, Double-Blind, Placebo-Controlled Study

Rheumatology ◽

10.1093/rheumatology/kev089.115 ◽

2015 ◽

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Radiographic Progression ◽

Safety Data ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 17A

A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis

Arthritis & Rheumatism ◽

10.1002/art.34330 ◽

2012 ◽

Vol 64 (6) ◽

pp. 1730-1739 ◽

Cited By ~ 100

Author(s):

Michael Yellin ◽

Igor Paliienko ◽

Andra Balanescu ◽

Semen Ter-Vartanian ◽

Vira Tseluyko ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Phase Ii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Long‐term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through 2 Years: Results from a Phase 3, Randomized, Double‐blind, Placebo‐controlled Study Conducted in Biologic‐naïve Patients with Active Psoriatic Arthritis

Arthritis & Rheumatology ◽

10.1002/art.42010 ◽

2021 ◽

Author(s):

Iain B. McInnes ◽

Proton Rahman ◽

Alice B. Gottlieb ◽

Elizabeth C. Hsia ◽

Alexa P. Kollmeier ◽

...

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Term Efficacy ◽

Interleukin 23

Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Active Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3523879 ◽

2020 ◽

Author(s):

Yoshiya Tanaka ◽

Tsutomu Takeuchi ◽

Hisashi Yamanaka ◽

Toshihiro Nanki ◽

Hisanori Umehara ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Inadequate Response ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Efficacy and Safety of E6011, an Anti‐Fractalkine Monoclonal Antibody, in Active Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results of a Randomized, Double‐blind, Placebo‐controlled Phase 2 study

Arthritis & Rheumatology ◽

10.1002/art.41555 ◽

2020 ◽

Author(s):

Yoshiya Tanaka ◽

Tsutomu Takeuchi ◽

Hisashi Yamanaka ◽

Toshihiro Nanki ◽

Hisanori Umehara ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Inadequate Response ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study

RMD Open ◽

10.1136/rmdopen-2014-000037 ◽

2015 ◽

Vol 1 (1) ◽

pp. e000037 ◽

Cited By ~ 12

Author(s):

Michael Schiff ◽

Bernard Combe ◽

Thomas Dörner ◽

Joel M Kremer ◽

Thomas W Huizinga ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Tnf Inhibitors ◽

Inadequate Response ◽

Efficacy And Safety ◽

Severe Rheumatoid Arthritis ◽

Phase 3 ◽

Double Blind ◽

Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy

SpringerPlus ◽

10.1186/s40064-015-0895-9 ◽

2015 ◽

Vol 4 (1) ◽

Cited By ~ 10

Author(s):

Kathryn Hobbs ◽

Atul Deodhar ◽

Brian Wang ◽

Bojena Bitman ◽

Joyce Nussbaum ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Dmard Therapy ◽